Rhumbline Advisers grew its holdings in Horizon Pharma PLC (NASDAQ:HZNP) by 3.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 210,843 shares of the biopharmaceutical company’s stock after purchasing an additional 6,871 shares during the period. Rhumbline Advisers owned approximately 0.13% of Horizon Pharma PLC worth $2,503,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of Montreal Can raised its position in shares of Horizon Pharma PLC by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 1,378 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in Horizon Pharma PLC during the 1st quarter worth approximately $151,000. Teacher Retirement System of Texas increased its holdings in Horizon Pharma PLC by 12.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 12,941 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 1,466 shares during the period. Stevens Capital Management LP bought a new stake in Horizon Pharma PLC during the 1st quarter worth approximately $173,000. Finally, Profund Advisors LLC increased its holdings in Horizon Pharma PLC by 0.8% during the 1st quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 112 shares during the period. 82.30% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/09/13/rhumbline-advisers-boosts-stake-in-horizon-pharma-plc-hznp.html.
HZNP has been the topic of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Horizon Pharma PLC in a report on Friday, June 16th. They set an “overweight” rating and a $13.00 target price on the stock. ValuEngine cut shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Piper Jaffray Companies set a $17.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Mizuho reissued a “hold” rating and issued a $12.00 price target (up previously from $9.00) on shares of Horizon Pharma PLC in a research note on Monday, August 28th. Finally, BidaskClub raised shares of Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $18.67.
Horizon Pharma PLC (NASDAQ:HZNP) opened at 13.42 on Wednesday. The company’s market capitalization is $2.19 billion. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $21.98. The firm has a 50-day moving average of $12.87 and a 200 day moving average of $13.11.
Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. The business had revenue of $289.51 million during the quarter, compared to analysts’ expectations of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The company’s revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.56 EPS. Equities research analysts predict that Horizon Pharma PLC will post $1.08 earnings per share for the current fiscal year.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.